Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 2 (2005), Issue 3 (March)

1. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios.
   Obstet Gynecol, 105(3): 642-3. [Abstract] [Full-text]
2. Predictive markers in breast and other cancers: a review.
   Clin Chem, 51(3): 494-503. [Abstract] [Full-text]
3. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
   Exp Cell Res, 304(2): 604-19. [Abstract] [Full-text]
4. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo.
   Clin Cancer Res, 11(5): 2008-17. [Abstract] [Full-text]
5. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
   Mol Cancer Ther, 4(3): 435-42. [Abstract] [Full-text]
6. Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells.
   Naunyn Schmiedebergs Arch Pharmacol, 371(2): 141-51. [Abstract] [Full-text]
7. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
   Med Hypotheses, 64(5): 997-1001. [Abstract] [Full-text]
8. Molecular therapy of head and neck cancer.
   Cancer Metastasis Rev, 24(1): 129-46. [Abstract] [Full-text]
9. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity.
   Endocr Relat Cancer, 12(1): 1-17. [Abstract] [Full-text]
10. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    J Pathol, 205(5): 577-84. [Abstract] [Full-text]
11. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
    Hum Pathol, 36(3): 250-61. [Abstract] [Full-text]
12. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.
    J Clin Oncol, 23(10): 2162-71. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.